Multiple myeloma trials in Spain

In Spain 82 Also abroad 704

82 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Where
Alicante, Badalona, Barcelona, Gijón, Girona, León, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga, Oviedo, Palma, Palma De Mallorca, Pamplona, Pozuelo de Alarcón, Santander, Santiago de Compostela, Sevilla, Terrassa, Valencia, Vitoria, Zaragoza
Age
18 years and over
People
410 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT05730036 · EU 2022-501396-62-00
Phase 1/2Taking people
A first time in man study to look at the safety of the experimental drug CCS1477 and what effects it has on cancers that affect the blood, bone marrow, lymph and lymphatic system.
Where
Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Valencia
Age
18 years and over
People
16
Run by
Cellcentric Limited
See details and how to join2024-519498-20-00 · EU 2024-519498-20-00
Phase 1Taking people
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Where
Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Pozuelo de Alarcón, Salamanca, Santander, Santiago de Compostela
Age
18 years and over
People
317 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT05137054 · EU 2023-506247-42-00
Phase 1/2Taking people
A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
Where
Badalona, Madrid, Valencia
Age
18 years and over
People
200 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05583617 · EU 2023-504484-16-00
Phase 3Taking people
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Where
Alicante, Gijón, Pozuelo de Alarcón, Terrassa, Valencia
Age
18 years and over
People
915 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT07222761 · EU 2024-519504-27-00
Phase 3Taking people
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Where
Alicante, Badalona, Barcelona, Granada, L'Hospitalet de Llobregat, Madrid, Murcia, Palma, Pamplona, Salamanca, Sevilla, Terrassa, Valencia, Vitoria
Age
18 years and over
People
270 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT07393282 · EU 2025-523252-31-00
Phase 2Taking people
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Where
Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, Murcia, Pamplona, Pozuelo de Alarcón, Salamanca, Santander, Sevilla
Age
18 years and over
People
510 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT04634552 · EU 2023-504581-29-00
Phase 4Taking people
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Where
Badalona, Barcelona, Madrid, Pamplona, Salamanca, Sevilla
Age
18 years and over
People
295 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05201781 · EU 2023-505530-10-00
Phase 3Taking people
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Where
Badalona, Barcelona, Granada, Jerez de la Frontera, L'Hospitalet de Llobregat, Madrid, Palma, Pozuelo de Alarcón, Salamanca, Terrassa, Valencia
Age
18 years and over
People
1,590 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05552222 · EU 2023-503442-30-00
Phase 1Taking people
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Where
Badalona, Barcelona, Madrid, Pamplona, Salamanca
Age
18 years and over
People
180 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05652335 · EU 2023-503679-12-00
No phaseTaking people
Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia
Where
Madrid
Age
10 years and over
People
210 worldwide
Run by
Leuko Labs, Inc.
See details and how to joinNCT06323447
Phase 2Taking people
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
Where
Badalona, Barcelona, Madrid, Pamplona, Salamanca, Santander, Sevilla
Age
18 years to 80 years
People
60 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07149857 · EU 2025-521975-30-00
Phase 3Taking people
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Where
Badalona, Barcelona, Galdakao, Granada, Madrid, Pozuelo de Alarcón, Salamanca, Valencia
Age
18 years and over
People
400 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07258511 · EU 2025-522007-18-00
Phase 2Taking people
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
Where
Barcelona, León, Madrid, Málaga, Pamplona, Valencia
Age
18 years and over
People
230 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07589634
Phase 3Taking people
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
Where
Badalona, Barcelona, Cáceres, Granada, Jerez de la Frontera, León, Lugo, Madrid, Pamplona, Pozuelo de Alarcón, Salamanca, Santander, Seville, Valencia, Zaragoza
Age
18 years and over
People
1,000 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07665450
Phase 3Taking people
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Where
Barcelona, Cáceres, León, Madrid, Marbella, Murcia, Palma
Age
18 years and over
People
810 worldwide
Run by
Celgene
See details and how to joinNCT05519085
Phase 1/2Taking people
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
Where
Badalona, Madrid, Pamplona, Salamanca
Age
18 years and over
People
226 worldwide
Run by
AstraZeneca
See details and how to joinNCT06106945 · EU 2023-508590-89-00
Phase 2Taking people
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Where
Badalona, Barcelona, Gijón, León, L'Hospitalet de Llobregat, Madrid, Murcia, Pamplona, Salamanca
Age
18 years and over
People
100 worldwide
Run by
C4 Therapeutics, Inc.
See details and how to joinNCT07284758 · EU 2025-524181-26-00
Phase 3Taking people
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Where
Badalona, Granada, Madrid, Palma, Pamplona, Salamanca, Santiago de Compostela
Age
18 years and over
People
440 worldwide
Run by
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06615479 · EU 2024-515279-37-00
Phase 2Not yet taking people in Spain
Elranatamab With Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Where
Albacete, Alicante, Badalona, Barcelona, Gijón, Granada, Las Palmas de Gran Canaria, Lugo, Madrid, Málaga, Murcia, Oviedo, Palma de Mallorca, Pamplona, Salamanca, Santander, Valencia, Vitoria-Gasteiz
Age
18 years and over
People
60
Run by
PETHEMA Foundation
See details and how to joinNCT07901868
Phase 3Taking people
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Where
Badalona, Barcelona, Cáceres, Girona, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona, Santander, Santiago de Compostela, Terrassa, Valencia
Age
18 years and over
People
1,060 worldwide
Run by
Pfizer
See details and how to joinNCT05623020 · EU 2024-514139-50-00
Phase 1/2Taking people
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
Where
Barcelona, Madrid, Pamplona, Salamanca
Age
18 years and over
People
387 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT03761108 · EU 2024-511454-45-00
Phase 1/2Taking people
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Where
Barcelona, Cáceres, Málaga, Sevilla
Age
18 years and over
People
246 worldwide
Run by
BeOne Medicines
See details and how to joinNCT04973605 · EU 2023-507751-30-00
Phase 1Taking people
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Where
Barcelona, Madrid, Pamplona, Salamanca
Age
18 years and over
People
165 worldwide
Run by
K36 Therapeutics, Inc.
See details and how to joinNCT05651932 · EU 2022-500801-41-00
Phase 3Taking people
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
Where
Badalona, Barcelona, El Palmar, Madrid, Salamanca, Santander, Seville
Age
18 years to 130 years
People
750 worldwide
Run by
AstraZeneca
See details and how to joinNCT07735637